How effective is targeted therapy for acute myeloid leukaemia?

AML is not one single disease pattern. A blood, bone marrow, or molecular test can show whether leukaemia cells carry a feature that a targeted medicine can recognise. The aim may be to reduce abnormal cells, help achieve remission, or control disease that has returned. Doctors judge the response using blood counts, examination, and sometimes repeat bone marrow testing. Results also depend on the person’s general health, the AML subtype, previous treatment, and whether the medicine is used alone or with chemotherapy.

A targeted drug may be considered at diagnosis, after a relapse, or when earlier treatment has not controlled the leukaemia. A response can change over time, so ongoing review matters even when blood counts improve.

Ask the haematology team which test supports the proposed medicine and what result would show that it is helping. Take the treatment exactly as prescribed and share every medicine, supplement, and new symptom with the team. Keep scheduled blood tests because they can reveal changes before you feel them. Treatment may be adjusted for blood-count changes, interactions, or reduced response.

You can read about [Targeted Therapy](/treatments/systemic-therapy/targeted-therapy/) and the condition in [Acute Myeloid Leukaemia](/conditions/acute-myeloid-leukaemia/).

Contact your oncology team promptly for a fever, chills, a new cough, breathlessness, unusual bleeding, black stools, severe weakness, or confusion. AML and its treatments can lower infection-fighting cells or platelets, so symptoms can need same-day assessment. Follow the personal emergency instructions supplied by your treatment centre.

Which molecular or cell test makes this treatment suitable for me? How will you measure response? When will those tests be repeated? What side effects should I report immediately? If the response is limited, what other treatment choices could be considered?